Brief: Sinomab Bioscience Says IND Application For SM17 Has Been Accepted By NMPA Of China
22/05/2023 02:33
May 22 (Reuters) - SinoMab BioScience Ltd 3681.HK :
* INVESTIGATIONAL NEW DRUG APPLICATION FOR SM17 HAS BEEN
ACCEPTED
BY NMPA OF CHINA
Further company coverage: 3681.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sinomab Bioscience
See all newsBrief: Sinomab Bioscience Posts HY Loss Of RMB127.4 Million
Brief: Sinomab Bioscience Says Fang Liang Resigns As Executive Director
Brief: Sinomab Bioscience Announces Major Deal For Disposal Of Suzhou Property And Facility For RMB280 MLN
Brief: SinoMab Bioscience Appoints Fang Liang As Executive Director
Brief: Hainan Haiyao Plans To Unload Stake In Sinomab Bioscience